Kidney function, proteinuria-related variables, and age were the most influential predictors and substantial heterogeneity was observed in cohort design, outcomes, prediction horizons, and validation methodology.
Abstract
Machine learning (ML) is increasingly applied to predicting chronic kidney disease (CKD) progression and kidney failure using routinely collected healthcare data, but the methodological quality and clinical applicability of these models remain uncertain. We hypothesised that ML models would show strong discrimination but be limited by inadequate external validation, inconsistent calibration, and high risk of bias (ROB), restricting clinical implementation.
We conducted a systematic review according to PRISMA guidance. Ovid MEDLINE, Embase, and CINAHL were searched from inception for studies evaluating ML models predicting CKD progression, kidney failure, or kidney replacement therapy using routinely collected healthcare data. Studies were synthesised by modelling framework, and ROB was assessed using PROBAST.
Fifty-two studies were included. ML models demonstrated favourable discrimination, with 37/52 studies reporting AUROC or concordance estimates ≥ 0.80. Where directly comparable, gains over conventional statistical models and established risk scores, including the Kidney Failure Risk Equation (KFRE), were often modest. External validation and calibration assessment were each reported in 19/52 studies, while 41/52 studies were at high ROB. Kidney function, proteinuria-related variables, and age were the most influential predictors. Substantial heterogeneity was observed in cohort design, outcomes, prediction horizons, and validation methodology. Inconsistent handling of proteinuria, missing data, and model-development workflows further limited assessment of transportability and real-world applicability.
ML models for CKD prognostic prediction demonstrate favourable discrimination across kidney outcomes. However, limited external validation, inconsistent calibration, and methodological heterogeneity restrict clinical implementation. Future progress requires rigorous validation, transparent methodology, and demonstration of real-world clinical utility.
These findings support a transition toward proactive, precision-based nephrology, however, requires standardisation of predictor criteria, optimisation of model sensitivity, broader external validation across diverse ethnic populations, and targeted solutions for implementation in low- and middle-income healthcare sett...
K. Kasparek, Julia Obersztyn, J. Bajer et al.· International Journal of Inn...· 0 citations
Introduction Artificial intelligence has been widely applied to chronic kidney disease (CKD), but the term ‘prediction” is frequently used for tasks ranging from contemporaneous disease classification to genuine forecasting of future renal outcomes. This systematic review examined this distinction while evaluating meth...
Aminu Bashir Suleiman, A. Garba, Aisha Mustapha Ahmad et al.· Frontiers in Artificial Inte...· 0 citations
Acute kidney injury affects about one in five hospitalised adults and substantially increases the risk of chronic kidney disease, yet conventional scoring systems poorly identify patients who will progress. This review critically appraises artificial intelligence and machine learning models for prognostication acro...
Venkateswaramurthy Nallasamy, M. A.· The Open Urology & Nephr...· 0 citations
The use of artificial intelligence, and particularly machine learning, is rapidly expanding in medicine. In nephrology, these approaches have generated growing interest owing to the availability of large clinical, biological, and administrative datasets, as well as the need for more accurate assessment of kidney functi...
A. Lanot, A. Boyer, N. Florens et al.· Néphrologie & Thérapeutique· 0 citations
While multimodal models offer notable performance advantages over unimodal approaches, their application in VHD remains limited and future research should prioritize the integration of heterogeneous data sources alongside rigorous external validation to ensure clinical generalizability and facilitate adoption in valvul...
V. Idakwo, C. Strote, C. Goelz et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.